Based on the key indicators related to Neurocrine Biosciences' liquidity, profitability, solvency, and operating efficiency, Neurocrine Biosciences is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in November. At this time, Neurocrine Biosciences' Cash And Short Term Investments are fairly stable compared to the past year. Net Receivables is likely to rise to about 461.3 M in 2024, whereas Retained Earnings are likely to drop (165 M) in 2024. Key indicators impacting Neurocrine Biosciences' financial strength include:
The essential information of the day-to-day investment outlook for Neurocrine Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Neurocrine Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neurocrine Biosciences.
Net Income
262.19 Million
Neurocrine
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Change To Inventory
Stock Based Compensation
Change To Account Receivables
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Sale Purchase Of Stock
Investments
Change Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Net Borrowings
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Short Term Investments
Other Liab
Other Assets
Long Term Debt
Common Stock Total Equity
Common Stock
Property Plant Equipment
Current Deferred Revenue
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Inventory
Deferred Long Term Liab
Non Current Liabilities Other
Long Term Investments
Long Term Debt Total
Net Invested Capital
Short Long Term Debt
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Tax Provision
Non Recurring
Probability Of Bankruptcy
Understanding current and past Neurocrine Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Neurocrine Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Neurocrine Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Neurocrine Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neurocrine Biosciences. Check Neurocrine Biosciences' Beneish M Score to see the likelihood of Neurocrine Biosciences' management manipulating its earnings.
Neurocrine Biosciences Stock Summary
Neurocrine Biosciences competes with Terns Pharmaceuticals, and Wave Life. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Neurocrine Bioscienc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 1150 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Neurocrine Biosciences Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Neurocrine Biosciences. It measures of how well Neurocrine is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Neurocrine Biosciences brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Neurocrine had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Neurocrine Biosciences has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Neurocrine Biosciences's current stock value. Our valuation model uses many indicators to compare Neurocrine Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurocrine Biosciences competition to find correlations between indicators driving Neurocrine Biosciences's intrinsic value. More Info.
Neurocrine Biosciences is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.74 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Neurocrine Biosciences is roughly 1.35 . At this time, Neurocrine Biosciences' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurocrine Biosciences' earnings, one of the primary drivers of an investment's value.
Neurocrine Biosciences Systematic Risk
Neurocrine Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neurocrine Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Neurocrine Biosciences correlated with the market. If Beta is less than 0 Neurocrine Biosciences generally moves in the opposite direction as compared to the market. If Neurocrine Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neurocrine Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neurocrine Biosciences is generally in the same direction as the market. If Beta > 1 Neurocrine Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Neurocrine Biosciences Thematic Clasifications
Neurocrine Biosciences is part of Obamacare Repeal investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Large healthcare related equities associated with Obamacare. Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal
This theme covers Large healthcare related equities associated with Obamacare. Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. Get More Thematic Ideas
Today, most investors in Neurocrine Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neurocrine Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neurocrine Biosciences growth as a starting point in their analysis.
Neurocrine Biosciences October 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neurocrine Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neurocrine Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neurocrine Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Neurocrine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neurocrine Biosciences's daily price indicators and compare them against related drivers.
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.